Nibix (Imatinib)

Imatinib, the active ingredient in Nibix, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It targets specific cancers such as chronic myeloid leukemia, Philadelphia‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumors, providing a targeted therapeutic option for patients with these diagnoses.

GNH USA supplies Nibix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution.

Imatinib is employed in oncology to inhibit tyrosine‑kinase driven malignancies.

- Chronic myeloid leukemia: reduces disease progression and improves survival by targeting BCR‑ABL‑positive cells. - Philadelphia‑positive acute lymphoblastic leukemia: achieves remission by blocking the same fusion protein that drives leukemic proliferation. - Gastrointestinal stromal tumor: inhibits c‑KIT and PDGFR signaling, leading to tumor shrinkage and disease control.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the extremities, especially ankles. - Fatigue: persistent tiredness not relieved by rest. - Muscle cramps: painful involuntary contractions. - Diarrhea: loose stools occurring intermittently. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Neutropenia: dangerously low white‑blood‑cell count increasing infection risk. - Hepatotoxicity: elevated liver enzymes indicating liver injury. - Cardiac failure: reduced heart function presenting with shortness of breath. - Severe bleeding: gastrointestinal or intracranial hemorrhage. - Pulmonary hypertension: elevated pressure in lung arteries. - Interstitial lung disease: inflammation of lung tissue causing cough and dyspnea.

Before initiating therapy, clinicians should assess baseline health status and monitor for potential complications.

- Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Liver function assessment: check hepatic enzymes before and during treatment. - Cardiac evaluation: obtain baseline ECG and monitor for signs of heart failure. - CYP3A4 interaction awareness: avoid strong inhibitors or inducers without dose adjustment. - Pregnancy and lactation counseling: discuss potential risks and advise contraception. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise imatinib levels. - Potent CYP3A4 inducers (e.g., rifampicin, St. John's wort): may reduce efficacy. - Concomitant use with antacids containing aluminum or magnesium: can impair absorption.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin): require dose adjustment. - Warfarin: may increase INR, necessitating closer coagulation monitoring. - Vaccines (live attenuated): consider timing to avoid reduced immune response.